Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 291

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 291
---
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

Item 15. Recent Sales of Unregistered Securities

In the prior three years, we have issued and sold the securities described below (giving effect to the Share Consolidation) without registering the securities under the Securities Act. None of these transactions involved any underwriter's underwriting discounts or commissions, or any public offering. We believe that each of the following issuances was exempt from registration under the Securities Act in reliance on Regulation S promulgated under the Securities Act regarding sales by an issuer in offshore transactions, Regulation D under the Securities Act, Regulation A under the Securities Act, Rule 701 under the Securities Act or pursuant to Section 4(a)(2) of the Securities Act regarding transactions not involving a public offering.

The Registrant issued $5,172,500 aggregate principal amount of 2025 Convertible Notes on May 3, 2024.

The Registrant issued approximately 2,770,047 common shares on June 28, 2024, including 1,461,250 common shares issued at $4.00 per share in the 2024 Equity Offering, 1,293,125 common shares issued upon conversion of the 2025 Convertible Notes at a conversion price of $4.00 per share and approximately 15,672 common shares issued in respect of accrued and unpaid interest on the 2025 Convertible Notes at a price of C$3.36 per share.

The Registrant issued 105,840 common shares to Yorkville as commitment shares pursuant to the SEPA on February 10, 2025. As of September 10, 2025, the Registrant has sold an additional 1,890,000 common shares to Yorkville Pursuant to the SEPA.

The Registrant issued 1,490,000 units, each unit consisting of one common share and one warrant to purchase one common share, on March 10, 2025 pursuant to Tier II of Regulation A under the Securities Act ("Regulation A"). As of September 10, 2025, the Registrant has issued 1,473,800 common shares upon the exercise of such warrants pursuant to Regulation A.

The Registrant issued 2,680,000 Private Warrants to Armistice on July 15, 2025.

The Registrant issued 125,000 and 20,000 common shares upon the exercise of 125,000 and 20,000 stock options